Table 1 Patient characteristics according to GNRI (n = 484).

From: Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib

 

No-risk (n = 258)

Low-risk (n = 91)

mod-major risk (n = 135)

P value

Age, years*

73 (67–78)

73 (68–78)

73 (68–78)

0.969

Sex, male:female

196:62

80:11

108:27

0.052

Etiology, HBV:HCV:NBNC

37:96:125

18:27:46

19:60:56

0.067

ECOG PS, 0:1

216:42

75:16

91:44

0.001

ALBI score*

− 2.35 (− 2.62 to − 2.01)

− 1.89 (− 2.24 to − 1.63)

− 1.75 (− 2.29 to − 1.55)

0.001

mALBI grade 1:2a:2b:3

143:75:40: 0

20:25:46:0

4:22:99:10

 < 0.001

Neo-GPS, 0:1:2

209:46:3

59:27:5

82:53:0

 < 0.001

NLR, < 4: ≥ 4

217:41

72:19

88:47

 < 0.001

O-PNI, < 40: ≥ 40

33:225

37:54

104:31

 < 0.001

CRP, < 1: ≥ 1

220:38

71:20

86:49

 < 0.001

AST, U/L*

35 (26–48)

43 (30–59)

54 (33–75)

 < 0.001

ALT, U/L*

26 (18–39)

28 (19–39)

32 (20–51)

0.011

Platelets, 104/µL*

14.3 (10.5–18.3)

13.4 (9.7–19.7)

15.4 (11.2–21.8)

0.035

Total bilirubin, mg/dL*

0.7 (0.6–1.0)

0.9 (0.6–1.1)

0.8 (0.6–1.1)

0.128

Albumin, g/dL*

3.9 (3.7–4.2)

3.6 (3.3–3.8)

3.1 (2.9–3.4)

 < 0.001

Prothrombin time, %*

89.2 (80.0–100.5)

90.0 (81.8–99.3)

86.1 (75.3–95.7)

0.046

AFP, ng/mL*

15.9 (5.0–346.49)

24.7 (4.3–378.0)

69.0 (8.0–1022.2)

0.019

DCP, mAU/mL*

124 (36–1345)

167 (57–2415)

562 (59–8926)

0.002

BCLC stage 0:A:B:C

4:17:116:121

3:8:42:38

1:6:45:83

0.053

Treatment line, first:later

187:71

58:33

85:50

0.637

  1. *Median (interquartile range). GNRI Geriatric nutritional risk index, Mod-major moderate to major, HBV hepatitis B virus, HCV hepatitis C virus, NBNC non-HBV-non-HCV, ECOG PS Eastern Cooperative Oncology Group performance status, ALBI score albumin-bilirubin score, mALBI grade modified ALBI grade, GNRI geriatric nutritional risk index, Neo-GPS neo-Glasgow prognostic score, NLR neutrophil-to-lymphocyte ratio, O-PNI Onodera’s prognostic nutritional index, CRP c-reactive protein, AST aspartate aminotransferase, ALT alanine aminotransferase, AFP alpha-fetoprotein, DCP des-gamma-carboxy prothrombin, BCLC stage Barcelona Clinic Liver Cancer stage.
Back to article page